Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

692.60 15.66 +2.31%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Piotroski F-Score
7 4 4 5

+8 more TTM periods

ROE
13.37% 13.51% 13.52% 13.02%
ROA
6.51% 6.50% 6.45% 6.46%
ROIC
6.03% 5.80% 5.56% 6.12%
Return on Tangible Assets
32.11% 36.57% 37.31% 27.84%
Average Days of Receivables
74.19 74.45 74.33 72.91
Free Cash Flow per Share
20.64 19.84 18.25 16.81
Free Cash Flow
7,637.00 7,362.00 6,789.00 6,337.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 3 Nov 2026